Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study

被引：6

作者：

Avallone, Gianluca ^{[1
,2
]}

Cavallo, Francesco ^{[2
]}

Tancredi, Annalisa ^{[3
]}

Maronese, Carlo A. ^{[4
,5
]}

Bertello, Martina ^{[6
]}

Fraghi, Alessandro ^{[7
]}

Conforti, Claudio ^{[8
,9
]}

Calabrese, Giulia ^{[10
]}

Di Nicola, Matteo R. ^{[11
]}

Oddenino, Giorgio A. ^{[12
]}

Gargiulo, Luigi ^{[13
,14
]}

Gori, Niccolo ^{[15
,16
]}

Loi, Camilla ^{[17
,18
]}

Romita, Paolo ^{[19
]}

Piras, Viviana ^{[20
]}

Bonzano, Laura ^{[21
]}

Tolino, Ersilia ^{[22
]}

Paolino, Giovanni ^{[11
,23
]}

Napolitano, Maddalena ^{[24
]}

Patruno, Cataldo ^{[25
]}

Nettis, Eustachio ^{[26
]}

Ferreli, Caterina ^{[27
]}

Roccuzzo, Gabriele ^{[2
]}

Marozio, Luca ^{[3
]}

Silvio, Martina ^{[4
,5
]}

Russo, Filomena ^{[6
]}

Bettolini, Luca ^{[7
]}

Gallo, Rosella ^{[12
]}

Mercuri, Santo R. ^{[11
,23
]}

Mastorino, Luca ^{[2
]}

Rossi, Mariateresa ^{[7
]}

Zalaudek, Iris ^{[8
]}

Argenziano, Giuseppe ^{[10
]}

Trave, Ilaria ^{[12
]}

Costanzo, Antonio ^{[13
,14
]}

Chiricozzi, Andrea ^{[15
,16
]}

Gurioli, Carlotta ^{[17
,18
]}

Foti, Caterina ^{[19
]}

Potenza, Concetta ^{[22
]}

Ferrucci, Silvia M. ^{[4
]}

Balato, Anna ^{[10
]}

Parodi, Aurora ^{[12
]}

Marzano, Angelo V. ^{[4
,5
]}

Ortoncelli, Michela ^{[2
]}

Ribero, Simone ^{[2
]}

Quaglino, Pietro ^{[2
]}

机构：

[1] Univ Turin, Dept Med Sci, Sect Dermatol, Via Cherasco 23, I-10121 Turin, Italy

[2] Univ Turin, Dept Med Sci, Dermatol Clin, Turin, Italy

[3] Univ Torino, St Anna Hosp, Physiopathol Reprod & IVF Unit, Obstet & Gynecol 1U,Dept Surg Sci, Turin, Italy

[4] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[5] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[6] Univ Siena, Santa Maria Alle Scotte Hosp, Dermatol Sect, Dept Med Surg & Neurol Sci, Siena, Italy

[7] Univ Brescia, Dermatol Dept, Brescia, Italy

[8] Univ Trieste, Maggiore Hosp, Dermatol Clin, Trieste, Italy

[9] Dermatol Res Hosp, IDI IRCCS, Rome, Italy

[10] Univ Campania Luigi Vanvitelli, Unit Dermatol, Naples, Italy

[11] IRCCS Osped San Raffaele, Unit Dermatol, Milan, Italy

[12] Univ Genoa, IRCCS Osped Policlin San Martino, Dept Hlth Sci, Sect Dermatol, Genoa, Italy

[13] IRCCS Humanitas Res Hosp, Dermatol Unit, Rozzano, MI, Italy

[14] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy

[15] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, UOC Dermatol, Rome, Italy

[16] Univ Cattolica Sacro Cuore, Dipartimento Med & Chirurg Traslaz, Dermatol, Rome, Italy

[17] IRCCS Azienda Osped Univ Bologna, Dermatol Unit, Bologna, Italy

[18] Univ Bologna, Dept Med & Surg Sci, Alma Mater Studiorum, Bologna, Italy

[19] Univ Bari Aldo Moro, Dept Precis & Regenerat Med & Ionian Area, Unit Dermatol, Bari, Italy

[20] Azienda Osped Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy

[21] Azienda USL IRCCS Reggio Emilia, Dermatol Unit, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy

[22] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, Polo Pontino, Rome, Italy

[23] Univ Vita Salute San Raffaele, Dermatol Clin, Milan, Italy

[24] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[25] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy

[26] Univ Bari Aldo Moro, Sch Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Bari, Italy

[27] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2024年 / 38卷 / 09期

关键词：

PLACEBO;

D O I：

10.1111/jdv.19794

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

BackgroundThere is limited epidemiological evidence on outcomes associated with dupilumab exposure during pregnancy; monitoring pregnancy outcomes in large populations is required.ObjectiveTo investigate the potential association between exposure to dupilumab in pregnant women with atopic dermatitis and any adverse pregnancy, neonatal, congenital and post-partum outcomes.MethodsWe performed a multicentre retrospective cohort study across 19 Italian tertiary referral hospital. Childbearing women were eligible if aged 18-49 years and carried out the pregnancy between 1 October 2018 and 1 September 2022.ResultsWe retrospectively screened records of 5062 patients receiving dupilumab regardless of age and gender, identifying 951 female atopic dermatitis patients of childbearing age, 29 of whom had been exposed to the drug during pregnancy (3%). The median duration of dupilumab treatment prior to conception was 22.5 weeks (range: 3-118). The median time of exposure to the drug during pregnancy was 6 weeks (range: 2-24). All the documented pregnancies were unplanned, and the drug was discontinued in all cases once pregnancy status was reported. The comparison of the study cohort and the control group found no significant drug-associated risk for adverse pregnancy, congenital, neonatal or post-partum outcomes. The absence of a statistically significant effect of exposure on the event was confirmed by bivariate analysis and multivariate analysis adjusted for other confounding factors.ConclusionsThis cohort of pregnant patients exposed to dupilumab adds to the existing evidence concerning the safety of biologic agents in pregnancy. No safety issues were identified regarding the primary outcome assessed. In clinical practice, these data provide reassurance in case of dupilumab exposure during the first trimester. However, the continuous use of dupilumab throughout pregnancy warrants further research.

引用

页码：1799 / 1808

页数：10

共 50 条

[21] Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
Hamilton, Jennifer D.
Suarez-Farinas, Mayte
Dhingra, Nikhil
Cardinale, Irma
Li, Xuan
Kostic, Ana
Ming, Jeffrey E.
Radin, Allen R.
Krueger, James G.
Graham, Neil
Yancopoulos, George D.
Pirozzi, Gianluca
Guttman-Yassky, Emma
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 134 (06) : 1293 - 1300
[22] Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Ferrucci, Silvia
Casazza, Giovanni
Zussino, Martina
Tavecchio, Simona
Marzano, Angelo V.
Tedeschi, Micol
JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
[23] Dupilumab reduces inflammatory biomarkers in pediatric patients with moderate-to-severe atopic dermatitis
Beck, Lisa A.
Muraro, Antonella
Boguniewicz, Mark
Chen, Zhen
Zahn, Joseph
Marco, Ainara Rodriguez
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (01)
[24] Clinically meaningful responses in moderate-to-severe atopic dermatitis patients treated with Dupilumab
de Bruin-Weller, M.
Eckert, L.
Simpson, E. L.
Cork, M. J.
Ardeleanu, M.
Chen, Z.
Shumel, B.
Rossi, A. B.
Graham, N. M. H.
Pirozzi, G.
Gadkari, A.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 116 - 116
[25] Efficacy of dupilumab in atopic comorbidities associated with moderate-to-severe adult atopic dermatitis
Nettis, Eustachio
Patella, Vincenzo
Lombardo, Carla
Detoraki, Aikaterini
Macchia, Luigi
Di Leo, Elisabetta
Carbonara, Monica
Canonica, Giorgio W.
Bonzano, Laura
ALLERGY, 2020, 75 (10) : 2653 - 2661
[26] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
Parker, Jennifer J.
Sugarman, Jeffrey L.
Silverberg, Nanette B.
Gonzalez, Mercedes Elena
Ramien, Michele L.
Teng, Joyce M. C.
Paller, Amy S.
PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
[27] Switching from dupilumab to abrocitinib in patients with moderate-to-severe atopic dermatitis: an analysis of responders and nonresponders to dupilumab
Silverberg, Jonathan, I
Simpson, Eric L.
Thyssen, Jacob P.
Pink, Andrew E.
Weidinger, Stephan
Chan, Gary
Lazariciu, Irina
Clibborn, Claire
Guler, Erman
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[28] Biomarkers in tear fluid of dupilumab-treated moderate-to-severe atopic dermatitis patients
Achten, Roselie
Thijs, Judith
van Luijk, Chantal
Knol, Edward
Delemarre, Eveline
de Graaf, Marlies
Bakker, Daphne
de Boer, Joke
van Wijk, Femke
de Bruin-Weller, Marjolein
CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (02): : 239 - 243
[29] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
Zheng, Y.
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
[30] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
Xu, Xinghua
Zheng, Yi
Zhang, Xin
He, Yanling
Li, Chengxin
ONCOTARGET, 2017, 8 (65) : 108480 - 108491

← 1 2 3 4 5 →